PHENOBARBITAL tablet

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

PHENOBARBITAL (UNII: YQE403BP4D) (PHENOBARBITAL - UNII:YQE403BP4D)

Pieejams no:

Bryant Ranch Prepack

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

1. Sedative 2. Anticonvulsant - For the treatment of generalized and partial seizures. Phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. Controlled Substance Phenobarbital is a Schedule IV drug. Dependence Barbiturates may be habit forming. Tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. Daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. A dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. The average daily dose for the barbiturate addict is usually about 1.5 g. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxic

Produktu pārskats:

Phenobarbital Tablets, USP 64.8 mg: White to off-white round, biconvex tablets debossed “T” above and “32” below the bisect on one side and plain on the other side. Available in bottles of 1000 tablets, NDC 63629-2402-1. Storage and Handling Store at 20°- 25°C (68°- 77°F) [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Autorizācija statuss:

unapproved drug other

Produkta apraksts

PHENOBARBITAL- PHENOBARBITAL TABLET
BRYANT RANCH PREPACK
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this_
_labeling has not been approved by FDA. For further information about
unapproved_
_drugs, click here._
----------
PHENOBARBITAL TABLETS, USP C-IV
RX ONLY
WARNING: MAY BE HABIT-FORMING
DESCRIPTION
The barbiturates are nonselective central nervous system (CNS)
depressants that are
primarily used as sedative-hypnotics. In subhypnotic doses, they are
also used as
anticonvulsants. The barbiturates and their sodium salts are subject
to control under the
Federal Controlled Substances Act.
Phenobarbital is a barbituric acid derivative and occurs as white,
odorless, small crystals
or crystalline powder that is very slightly soluble in water; soluble
in alcohol, in ether, and
in solutions of fixed alkali hydroxides and carbonates; sparingly
soluble in chloroform.
Phenobarbital is 5-ethyl-5- phenylbarbituric acid. Phenobarbital is a
substituted
pyrimidine derivative in which the basic structure is barbituric acid,
a substance that has
no CNS activity. CNS activity is obtained by substituting alkyl,
alkenyl, or aryl groups on
the pyrimidine ring. It has the following structural formula:
C
H N O M.W. = 232.24
12
12
2
3
Each phenobarbital tablet contains 16.2 mg, 32.4 mg, 64.8 mg, or 97.2
mg of
phenobarbital, USP.
INACTIVE INGREDIENTS INCLUDE: colloidal silicon dioxide, lactose
monohydrate,
microcrystalline cellulose, sodium starch glycolate and magnesium
stearate.
CLINICAL PHARMACOLOGY
Barbiturates are capable of producing all levels of CNS mood
alteration, from excitation
to mild sedation, hypnosis, and deep coma. Overdosage can produce
death. In high
enough therapeutic doses, barbiturates induce anesthesia.
Barbiturates depress the sensory cortex, decrease motor activity,
alter cerebellar
function, and produce drowsiness, sedation, and hypnosis.
Barbiturate-induced sleep differs from physiologic sleep. Sleep
laboratory studies have
demonstrated that barbiturates reduce the amount of t